Anti-γ-aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights.

IF 6.6 1区 医学 Q1 CLINICAL NEUROLOGY
Epilepsia Pub Date : 2025-09-30 DOI:10.1111/epi.18654
Naveen K Paramasivan, Jennifer A McCombe, Andrea Stabile, James P Fryer, Abhigyan Datta, Mohamed Rezk, Nihar Upadhyay, Jeffrey W Britton, Eoin P Flanagan, Andrew McKeon, John R Mills, Sean J Pittock, Anastasia Zekeridou, Divyanshu Dubey
{"title":"Anti-γ-aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights.","authors":"Naveen K Paramasivan, Jennifer A McCombe, Andrea Stabile, James P Fryer, Abhigyan Datta, Mohamed Rezk, Nihar Upadhyay, Jeffrey W Britton, Eoin P Flanagan, Andrew McKeon, John R Mills, Sean J Pittock, Anastasia Zekeridou, Divyanshu Dubey","doi":"10.1111/epi.18654","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>γ-Aminobutyric acid B receptor (GABA<sub>B</sub>R)-IgG (immunoglobulin G) is an intermediate-risk paraneoplastic autoantibody often associated with seizures. We aimed to assess the clinical and oncological features of GABA<sub>B</sub>R-IgG autoimmune encephalitis (AE) and evaluate the performance of antibody testing.</p><p><strong>Methods: </strong>Patients testing positive for GABA<sub>B</sub>R-IgG in serum/cerebrospinal fluid (CSF) at Mayo Clinic Neuroimmunology Laboratory were identified. Archived sera were retested by cell-based assay (CBA) at 1:100 and 1:200 dilutions. A live-cell flow cytometry-based assay (LCFBA) was developed and validated using archived sera and CSF. True positivity included patients with classic presentations of GABA<sub>B</sub>R-IgG AE or oncological explanations for antibody presence.</p><p><strong>Results: </strong>Eighty-six patients (median age 63 years; 43 female) presented with classic presentations of GABA<sub>B</sub>R-IgG AE: encephalopathy with prominent seizures (n = 55), status epilepticus (n = 23), and rapidly progressive dementia (n = 8). In addition, 44 patients (33%) had a false-positive result for GABA<sub>B</sub>R-IgG characterized by non-specific symptoms/alternate diagnoses. Malignancy was identified in 78% of true-positive patients, predominantly small cell lung carcinoma (SCLC). Testing serum at 1:100 dilution on CBA and using tissue immunofluorescence assay (IFA) in serum and CSF improved the identification of true-positive patients (p < 0.001). CBA at 1:100 dilution performed better than conventional CBA (at 1:10 dilution, p < 0.001) and tissue IFA (p = 0.031). An in-house LCFBA showed 100% sensitivity and specificity in CSF, performing similarly to conventional CBA (p = 0.125) in CSF, but better than tissue IFA (p = 0.031). Furthermore, serum LCFBA performed better than conventional CBA (p = 0.022) and tissue IFA (p = 0.006). LCFBA had the highest diagnostic accuracy and was closely followed by CBA at 1:100 dilution.</p><p><strong>Significance: </strong>GABA<sub>B</sub>R-IgG AE often presents as encephalopathy with seizures or status epilepticus in the context of an underlying SCLC. Multimodal evaluation using tissue IFA and fixed CBA at higher dilutions improves detection of true cases. LCFBA performs very well as a diagnostic test with very high sensitivity and specificity.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/epi.18654","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: γ-Aminobutyric acid B receptor (GABABR)-IgG (immunoglobulin G) is an intermediate-risk paraneoplastic autoantibody often associated with seizures. We aimed to assess the clinical and oncological features of GABABR-IgG autoimmune encephalitis (AE) and evaluate the performance of antibody testing.

Methods: Patients testing positive for GABABR-IgG in serum/cerebrospinal fluid (CSF) at Mayo Clinic Neuroimmunology Laboratory were identified. Archived sera were retested by cell-based assay (CBA) at 1:100 and 1:200 dilutions. A live-cell flow cytometry-based assay (LCFBA) was developed and validated using archived sera and CSF. True positivity included patients with classic presentations of GABABR-IgG AE or oncological explanations for antibody presence.

Results: Eighty-six patients (median age 63 years; 43 female) presented with classic presentations of GABABR-IgG AE: encephalopathy with prominent seizures (n = 55), status epilepticus (n = 23), and rapidly progressive dementia (n = 8). In addition, 44 patients (33%) had a false-positive result for GABABR-IgG characterized by non-specific symptoms/alternate diagnoses. Malignancy was identified in 78% of true-positive patients, predominantly small cell lung carcinoma (SCLC). Testing serum at 1:100 dilution on CBA and using tissue immunofluorescence assay (IFA) in serum and CSF improved the identification of true-positive patients (p < 0.001). CBA at 1:100 dilution performed better than conventional CBA (at 1:10 dilution, p < 0.001) and tissue IFA (p = 0.031). An in-house LCFBA showed 100% sensitivity and specificity in CSF, performing similarly to conventional CBA (p = 0.125) in CSF, but better than tissue IFA (p = 0.031). Furthermore, serum LCFBA performed better than conventional CBA (p = 0.022) and tissue IFA (p = 0.006). LCFBA had the highest diagnostic accuracy and was closely followed by CBA at 1:100 dilution.

Significance: GABABR-IgG AE often presents as encephalopathy with seizures or status epilepticus in the context of an underlying SCLC. Multimodal evaluation using tissue IFA and fixed CBA at higher dilutions improves detection of true cases. LCFBA performs very well as a diagnostic test with very high sensitivity and specificity.

抗γ-氨基丁酸B受体自身免疫性脑炎:临床表现和诊断见解。
目的:γ-氨基丁酸B受体(GABABR)-IgG(免疫球蛋白G)是一种中等危险的副肿瘤自身抗体,常与癫痫发作有关。我们旨在评估GABABR-IgG自身免疫性脑炎(AE)的临床和肿瘤学特征,并评估抗体检测的性能。方法:在梅奥诊所神经免疫学实验室对血清/脑脊液中GABABR-IgG阳性的患者进行鉴定。存档的血清以1:100和1:200的稀释度用细胞法(CBA)重新检测。利用存档的血清和脑脊液,开发并验证了一种基于活细胞流式细胞仪的检测方法(LCFBA)。真阳性包括典型表现为GABABR-IgG AE或抗体存在的肿瘤学解释的患者。结果:86例患者(中位年龄63岁;43例女性)表现为GABABR-IgG AE的典型表现:脑病伴显著癫痫发作(n = 55)、癫痫持续状态(n = 23)和快速进展性痴呆(n = 8)。此外,44名患者(33%)出现了以非特异性症状/替代诊断为特征的gabab - igg假阳性结果。78%的真阳性患者为恶性肿瘤,主要为小细胞肺癌(SCLC)。以1:100稀释CBA检测血清,并在血清和脑脊液中使用组织免疫荧光法(IFA)提高了对真阳性患者的识别(p意义:在潜在的SCLC背景下,GABABR-IgG AE通常表现为癫痫发作或癫痫持续状态的脑病。使用组织IFA和较高稀释度的固定CBA进行多模态评估可以提高对真实病例的检测。LCFBA作为一种诊断试验具有很高的灵敏度和特异性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Epilepsia
Epilepsia 医学-临床神经学
CiteScore
10.90
自引率
10.70%
发文量
319
审稿时长
2-4 weeks
期刊介绍: Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信